Aug 12, 2020
Innovent and Eli Lilly Announce Acceptance of a Supplemental New Drug Application of TYVYT® (Sintilimab Injection) in Combination with Gemcitabine and Platinum as First-Line Therapy in Squamous Non-Small Cell Lung Cancer in China
Jun 22, 2020
LUNGevity and EGFR Resisters Collaborate on Lung Cancer Research Awards
Jun 18, 2020
Association Of Community Cancer Centers Releases Preliminary Findings From Survey On Advanced Non-Small Cell Lung Cancer Care
Jun 05, 2020
Mirati Therapeutics to Present at 41st Annual Goldman Sachs Global Healthcare Conference
May 30, 2020
Guardant360 test results may provide prognostic information beyond the detection of actionable biomarkers for ALK-rearranged NSCLC patients
May 29, 2020
Amgen Presents New AMG 510 Clinical Data Across Multiple Solid Tumors During ASCO20 Virtual Scientific Program
May 29, 2020
Libtayo® (cemiplimab-rwlc) Longer-term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ASCO 2020 Show Durable Responses that Deepen Over Time
May 29, 2020
Lilly's CYRAMZA® (ramucirumab) Receives FDA Approval as First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
May 19, 2020
Small Cell Lung Cancer (SCLC) Market Insights, Epidemiology and Forecast to 2030
May 18, 2020
Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring Exon 20 Insertion Mutations
May 15, 2020
Mirati Therapeutics To Present Preclinical Data From Investigational Pipeline Of Novel Therapeutics At 2020 American Association For Cancer Research Virtual Annual Meeting II
May 13, 2020
Sanofi to showcase oncology portfolio and innovative pipeline at ASCO20 Virtual Scientific Program
May 12, 2020
Non-Small Cell Lung Cancer (NSCLC) Market Forecasts to 2030: A Comprehensive Insight
May 08, 2020
Lilly Receives U.S. FDA Approval for Retevmo(TM) (selpercatinib), the First Therapy Specifically for Patients with Advanced RET-Driven Lung and Thyroid Cancers
May 08, 2020
FDA Approves First Therapy for Patients with Lung and Thyroid Cancers with a Certain Genetic Mutation or Fusion
May 07, 2020
Bridge Biotherapeutics Announces the IND Clearance of BBT-176, an EGFR TKI for NSCLC, in South Korea
May 07, 2020
Mirati Therapeutics Reports First Quarter 2020 Financial Results And Recent Corporate Updates
May 06, 2020
Novartis announces FDA approval of MET inhibitor Tabrecta(TM) for metastatic non-small cell lung cancer with METex14
May 06, 2020
FDA Approves First Targeted Therapy to Treat Aggressive Form of Lung Cancer
May 05, 2020
Libtayo® (cemiplimab) Shows Clinically-Meaningful and Durable Responses in Second-line Advanced Basal Cell Carcinoma